International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)

Active, not recruitingOBSERVATIONAL
Enrollment

5,399

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
COVID-19
Trial Locations (11)

17011

Onom Foundation and Liver Center, Ulaanbaatar

Unknown

National Institute for Biomedical Research/Institut National de Recherche Biomédicale (INRB), Gombe

Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI), Conakry

National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Jakarta - RSU Kabupaten Tangerang, Tangerang

Partnership for Research in Vaccines and Infectious Diseases in Liberia (PREVAIL) - Duport Road Health Center, Monrovia

University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako, Bamako

"Hospital Regional de Alta Especialidad Ciudad Salud HRAE-CS", Tapachula

Hospital General Dr. Manuel Gea Gonzalez (HGMGG), Mexico City

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ),, Mexico City

Instituto Nacional de Enfermedades Respiratorias (INER), Mexico City

Hospital General Dr. Aurelio Valdivieso (HGAV), Oaxaca City

All Listed Sponsors
collaborator

Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo

OTHER

collaborator

Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI)

UNKNOWN

collaborator

Partnership for Research on Ebola Virus in Liberia (PREVAIL)

NETWORK

collaborator

University Clinical Research Center, Mali

OTHER

collaborator

Onom Foundation and Liver Center

UNKNOWN

collaborator

Mexican Emerging Infectious Diseases Clinical Research Network

NETWORK

collaborator

Ina-Respond

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05096091 - International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE) | Biotech Hunter | Biotech Hunter